Overview
Congenital dyserythropoietic anemia, type III, is a rare genetic disorder characterized by ineffective erythropoiesis leading to chronic anemia and extramedullary hematopoiesis. It primarily affects red blood cell production, resulting in morphological abnormalities and impaired function [Not directly covered in provided abstracts].Diagnosis
Clinical Presentation: Chronic anemia, splenomegaly, and sometimes jaundice [Not directly covered in provided abstracts].
Laboratory Findings: Abnormal peripheral blood smear showing megaloblastic or hypochromic macrocytic anemia, increased reticulin fibers in the bone marrow [Not directly covered in provided abstracts].
Genetic Testing: Identification of mutations in specific genes (e.g., AGL, PNLIPRP1) associated with the condition [Not directly covered in provided abstracts].Management
Supportive Care: Regular blood transfusions to manage anemia [Not directly covered in provided abstracts].
Iron Chelation: Consider iron chelation therapy if iron overload is present [Not directly covered in provided abstracts].
Hydroxyurea: May be used in some cases to improve erythropoietic function [Not directly covered in provided abstracts].Special Populations
Pregnancy: Prophylactic administration of antithrombin III concentrate (3,000 U three times weekly) can effectively reduce thrombin hyperactivity without documented thrombotic events 1. Monitor specific hemostatic markers like FPA, TAT, and F1 + 2 levels closely 1.Key Recommendations
Monitor Hemostatic Markers During Pregnancy: Regularly assess fibrinopeptide A (FPA), thrombin-antithrombin III complex (TAT), and prothrombin fragment F1 + 2 levels in pregnant women with congenital antithrombin III deficiency to guide prophylactic antithrombin III administration 1. (Evidence: Moderate)
Prophylactic Antithrombin III Administration: Administer antithrombin III concentrate prophylactically in pregnant women with congenital antithrombin III deficiency to mitigate thrombin hyperactivity 1. (Evidence: Moderate)
Adjust Dosage Based on Levels: Adjust dosing of antithrombin III based on measured levels and response, particularly focusing on reduction of elevated FPA levels 1. (Evidence: Moderate)References
1 Kario K, Matsuo T, Kodama K, Matsuo M. Prophylactic antithrombin III administration during pregnancy immediately reduces the thrombin hyperactivity of congenital antithrombin III deficiency by forming thrombin-antithrombin III complexes. Thrombosis research 1992. link90305-t)